4.3 Article

Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer

Journal

ONCOTARGET
Volume 8, Issue 2, Pages 2423-2436

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.13682

Keywords

EMT; early breast cancer; tumor aggressiveness; alternative splicing; EMT ratio

Ask authors/readers for more resources

Epithelial-to-mesenchymal transition (EMT) has been shown to be associated with tumor progression and metastasis. During this process in breast cancer, a crucial role is played by alternative splicing systems. To identify a new early prognostic marker of metastasis, we evaluated EMT-related gene expression in breast cell lines, and in primary tumor tissue from 31 patients with early breast cancer, focusing our attention on EMT-related splicing factors ESRP1, ESRP2 and RBFOX2. Results showed that the expression patterns of these genes were indicative of the onset of EMT in in-vitro models, but not in tissue samples. However, the ratio between ESRP1 or ESRP2 and RBFOX2 significantly decreased during EMT and positively correlated with the EMT-specific phenotype in cell models, representing a promising prognostic markers. Low ESRP1/RBFOX2 ratio value was associated with a higher risk of metastasis (p < 0.005) in early breast cancer patients, regardless other clinical features. A cutoff of ratio of 1.067 was determined by ROC curve analysis (AUC 0.8375; 95% CI 0.6963-0.9787). Our study show evidence that a decrease in this ratio correlates with cancer progression. The results provide a rationale for using ESRP1/RBFOX2 ratio as a new prognostic biomarker for the early prediction of metastatic potential in breast cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Dentistry, Oral Surgery & Medicine

Identification of a novel RAB3IP-HMGA2 fusion transcript in an adult head and neck rhabdomyosarcoma

Alessandro De Vita, Anna Ferrari, Giacomo Miserocchi, Silvia Vanni, Chiara Domizio, Eugenio Fonzi, Valentina Fausti, Federica Recine, Massimo Bassi, Angelo Campobassi, Chiara Liverani, Chiara Spadazzi, Claudia Cocchi, Giovanni De Luca, Federica Pieri, Lorena Gurrieri, Giandomenico Di Menna, Sebastiano Calpona, Alberto Bongiovanni, Giovanni Martinelli, Toni Ibrahim, Laura Mercatali

ORAL DISEASES (2022)

Article Oncology

Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy

Federica Recine, Alessandro De Vita, Valentina Fausti, Federica Pieri, Alberto Bongiovanni, Eugenia Franchini, Roberto Casadei, Maria Cristina Falasconi, Devil Oboldi, Federica Matteucci, Maria Caterina Pallotti, Laura Mercatali, Nada Riva, Lorena Gurrieri, Silvia Vanni, Chiara Liverani, Giacomo Miserocchi, Chiara Spadazzi, Claudia Cocchi, Toni Ibrahim

Summary: NTRK-rearranged spindle cell neoplasms are a new type of tumor with diverse histologies and clinical behavior. Several targeted therapies have been approved for tumors harboring NTRK fusions. In this case, treatment with larotrectinib resulted in tumor shrinkage and no drug-related toxicity.

FRONTIERS IN ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences

Alessandro De Vita, Silvia Vanni, Giacomo Miserocchi, Valentina Fausti, Federica Pieri, Chiara Spadazzi, Claudia Cocchi, Chiara Liverani, Chiara Calabrese, Roberto Casadei, Federica Recine, Lorena Gurrieri, Alberto Bongiovanni, Toni Ibrahim, Laura Mercatali

Summary: This study investigated the molecular and pharmacological aspects of GCTB and DF, revealing the expression changes in bone-vicious-cycle- and neoangiogenesis-related genes. The combination therapy of denosumab and lenvatinib was found to be a promising strategy for these diseases, as supported by in vitro, in vivo, and clinical observations.

BIOMEDICINES (2022)

Review Oncology

Use of Sequential Multiple Assignment Randomized Trials (SMARTs) in oncology: systematic review of published studies

Giulia Lorenzoni, Elisabetta Petracci, Emanuela Scarpi, Ileana Baldi, Dario Gregori, Oriana Nanni

Summary: Sequential multiple assignments randomized trials (SMARTs) are an experimental design in which patients are randomized multiple times according to pre-specified decision rules. This study investigates the current state of SMART designs in oncology and identifies a discrepancy between the statistical literature and actual procedures used in cancer clinical trials. A systematic review found that SMART designs in oncology are still limited and there is a need for formal reporting guidelines.

BRITISH JOURNAL OF CANCER (2023)

Article Endocrinology & Metabolism

HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors

Chiara Liverani, Chiara Spadazzi, Toni Ibrahim, Federica Pieri, Flavia Foca, Chiara Calabrese, Alessandro De Vita, Giacomo Miserocchi, Claudia Cocchi, Silvia Vanni, Giorgio Ercolani, Davide Cavaliere, Nicoletta Ranallo, Elisa Chiadini, Giovanna Prisinzano, Stefano Severi, Maddalena Sansovini, Giovanni Martinelli, Alberto Bongiovanni, Laura Mercatali

Summary: Neuroendocrine neoplasms (NENs) are a rare group of tumors with a wide range of clinical presentations. Lenvatinib, a multi-tyrosine kinase inhibitor, has been shown to be effective in treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The overexpression of HRAS in tumor tissue may be a potential biomarker for lenvatinib response.

FRONTIERS IN ENDOCRINOLOGY (2023)

Article Biochemistry & Molecular Biology

Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need

Silvia Vanni, Valentina Fausti, Eugenio Fonzi, Chiara Liverani, Giacomo Miserocchi, Chiara Spadazzi, Claudia Cocchi, Chiara Calabrese, Lorena Gurrieri, Nada Riva, Federica Recine, Roberto Casadei, Federica Pieri, Ania Naila Guerrieri, Massimo Serra, Toni Ibrahim, Laura Mercatali, Alessandro De Vita

Summary: Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) are considered as a spectrum of the same disease entity, representing common adult soft tissue sarcoma (STS) of the extremities. MFS has a high rate of local recurrences, while UPS is prone to distant recurrence and poor prognosis. Differential diagnosis is challenging due to their heterogeneous morphology, and both lack diagnostic and prognostic biomarkers. Genomic profiling combined with pharmacological approaches can identify predictive biomarkers for differential diagnosis, prognosis, and targeted therapy, improving STS patient management.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Immunology

Combining preclinical tools and models to unravel tumor complexity: Jump into the next dimension

Giacomo Miserocchi, Martine Bocchini, Michela Cortesi, Chiara Arienti, Alessandro De Vita, Chiara Liverani, Laura Mercatali, Sara Bravaccini, Paola Ulivi, Michele Zanoni

Summary: Tumors are complex and heterogeneous diseases connected with surrounding and distant tissues. Developing functional and realistic tumor organs is a major challenge, but efforts have been made to improve and integrate in vitro and in vivo models to better understand the disease biology and improve therapeutic approaches.

FRONTIERS IN IMMUNOLOGY (2023)

Article Oncology

Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin

Valentina Fausti, Alessandro De Vita, Silvia Vanni, Virginia Ghini, Lorena Gurrieri, Nada Riva, Roberto Casadei, Marco Maraldi, Giorgio Ercolani, Davide Cavaliere, Carlo Alberto Pacilio, Federica Pieri, Flavia Foca, Alberto Bongiovanni, Nicoletta Ranallo, Sebastiano Calpona, Giovanni Luca Frassineti, Toni Ibrahim, Laura Mercatali

Summary: High NLR, PLR, and SII are associated with worse PFS in second-line STS patients. Trabectedin-treated patients have a better PFS when LMR is low, while patients treated with other regimens have a worse PFS when LMR is low. Patients showing a high LMR seem to have high levels of M2 intratumoral macrophages.

CANCERS (2023)

Review Oncology

ARID1A in cancer: Friend or foe?

Beatrice Fontana, Giulia Gallerani, Irene Salamon, Ilaria Pace, Roberta Roncarati, Manuela Ferracin

Summary: ARID1A is a chromatin regulatory protein that plays a role in maintaining accessibility at promoters and enhancers to regulate gene expression. It is frequently altered in various human cancers and can act as a tumor suppressor or oncogene depending on the tumor type and context. ARID1A mutations are observed in approximately 10% of tumors, including endometrial, bladder, gastric, liver, biliopancreatic cancer, some ovarian cancer subtypes, and aggressive cancers of unknown primary. Its loss is generally associated with disease progression and worse prognostic features. However, the association of ARID1A genetic alterations with patient prognosis is controversial. Nevertheless, ARID1A loss of function can be targeted with inhibitory drugs based on synthetic lethality mechanisms.

FRONTIERS IN ONCOLOGY (2023)

Article Oncology

The NF-Y splicing signature controls hybrid EMT and ECM-related pathways to promote aggressiveness of colon cancer

Giovanna Rigillo, Silvia Belluti, Virginia Campani, Gregorio Ragazzini, Mirko Ronzio, Giacomo Miserocchi, Beatrice Bighi, Laura Cuoghi, Valentina Mularoni, Vincenzo Zappavigna, Diletta Dolfini, Laura Mercatali, Andrea Alessandrini, Carol Imbriano

Summary: Aberrant splicing of NF-YAl transcript is associated with aggressive mesenchymal CRC and predicts shorter survival. CRC cells overexpressing NF-YAl exhibit altered cell behavior and transcription of genes involved in cell adhesion and epithelial-mesenchymal transition. These findings suggest that NF-YAl may serve as a prognostic factor for CRC and splice-switching strategies could be used to reduce metastatic progression.

CANCER LETTERS (2023)

Article Biochemistry & Molecular Biology

Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer

Maria Concetta Cursano, Emilio Francesco Giunta, Emanuela Scarpi, Chiara Casadei, Alessandra Virga, Paola Ulivi, Sara Bleve, Nicole Brighi, Giorgia Ravaglia, Francesco Pantano, Vincenza Conteduca, Daniele Santini, Ugo De Giorgi

Summary: This study evaluated the prevalence of DNA damage repair (DDR) gene mutations in castration-resistant prostate cancer (CRPC) patients and their impact on clinical outcomes related to bone metastases. The results showed that DDR mutations were associated with larger bone metastases volume, but did not affect skeletal-related events incidence and time to onset.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series

Lorena Gurrieri, Laura Mercatali, Toni Ibrahim, Valentina Fausti, Monia Dall'Agata, Nada Riva, Nicoletta Ranallo, Giuseppe Pasini, Marcella Tazzari, Flavia Foca, Daniela Bartolini, Luca Riccioni, Chiara Cavatorta, Federico Paolo Morigi, Jenny Bulgarelli, Claudia Cocchi, Virginia Ghini, Luigino Tosatto, Giovanni Martinelli, Andrea Pession, Laura Ridolfi

Summary: The purpose of this retrospective study was to investigate the role of the immune system in glioblastoma (GBM) and identify prognostic markers related to overall survival (OS) and progression-free survival (PFS). The study analyzed inflammatory markers in the blood of 95 patients and compared the impact of circulating and inflammatory markers within the tumor microenvironment (TME) in 31 patients. Results showed that SII and specific immune infiltrating subsets expressed in the vascular/perivascular area could serve as predictive markers for response to treatment and prognosis.

JOURNAL OF NEURO-ONCOLOGY (2023)

Meeting Abstract Oncology

Dissecting the role of CDK4 in liposarcoma

Silvia Vanni, Graziana Gallo, Valentina Fausti, Giacomo Miserocchi, Chiara Liverani, Chiara Spadazzi, Claudia Cocchi, Chiara Calabrese, Giovanni De Luca, Massimo Bassi, Manlio Gessaroli, Angelo Campobassi, Federica Pieri, Giorgio Ercolani, Davide Cavaliere, Lorena Gurrieri, Nada Riva, Giovanni Martinelli, Laura Mercatali, Alessandro De Vita

CANCER RESEARCH (2023)

Meeting Abstract Oncology

A multimodel preclinical platform to evaluate photodynamic therapy as a strategy to reduce local recurrence in myxofibrosarcoma and osteosarcoma

Chiara Spadazzi, Micaela Pannella, Chiara Bellotti, Elisa Martella, Silvia Vanni, Alessandro De Vita, Chiara Liverani, Giacomo Miserocchi, Claudia Cocchi, Chiara Calabrese, Valentina Fausti, Roberto Casadei, Federica Pieri, Ania Naila Guerrieri, Giovanni Martinelli, Greta Varchi, Enrico Lucarelli, Laura Mercatali, Toni Ibrahim

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Autologous ECM-composed scaffolds and zebrafish PDXs for individualized theranostics in rare neuroendocrine neoplasms

Chiara Calabrese, Giacomo Miserocchi, Silvia Vanni, Alessandro De Vita, Alberto Bongiovanni, Chiara Spadazzi, Claudia Cocchi, Nicoletta Ranallo, Federica Pieri, Michela Tebaldi, Flavia Foca, Giorgio Ercolani, Davide Cavaliere, Carlo Alberto Pacilio, Giovanni Martinelli, Laura Mercatali, Chiara Liverani

CANCER RESEARCH (2023)

No Data Available